“#SLEDAI should be scored when there is joint swelling (not just tenderness)—note that only 48% of pts with tenderness will have u/s evidence of inflammation” – Prof E Vital #EULAR2022 @rheumnow https://t.co/hhsZ9wMAWs

Dr. Werth shared her evidence based algorithm for managing cutaneous lupus published here: https://t.co/RytrxLdLHK #EULAR2022 @rheumnow https://t.co/wq28btM24U

• https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41480

OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF

OP0280 WIN-lupus study eval if #SLE LN pts in remission can stop Rx. In pts who continued vs. stopped Rx: renal relapse 12% vs. 27%, p=0.08 and severe SLE flare 12 vs 32%, p=0.03; pts relapsing had inc baseline UPCR/SLEDAI score; +APS; lower lymphs/C3 . #EULAR2022 @rheumnow

Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 https://t.co/yMJcMAFSh6

Promising! Prof Schett presents the 1st 5 #SLE pts who received CAR T cell therapy - all went into sustained remission off of meds: new B cells reconstituted at 100 days but SLE did not. OP0279 #EULAR2022 @rheumnow https://t.co/o3Ehp55C4Q

OP0285 Voclosoporin effective in #lupusNephritis from AURA-LV and AURORA1 to achieve EULAR/ERA nephritis targets (proteinuria < 0.7 mg/mg and pred < 7.5 mg/d) at 1 year @AuriniaPharma #EULAR2022 @rheumnow https://t.co/0GoCgP98F2